Skip to Content

Sodium Zirconium Cyclosilicate Dosage

Medically reviewed by Last updated on Oct 21, 2020.

Applies to the following strengths: 5 g; 10 g

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Hyperkalemia

Initial dose: 10 g orally 3 times a day for up to 48 hours
-Dose should be adjusted based on serum potassium level and desired target range; dose may be up-titrated at weekly or greater intervals in 5 g increments
Maintenance dose: 10 g orally once a day; range: 5 g once a day every other day to 15 g once a day

-This drug should not be used for the emergency treatment of life-threatening hyperkalemia because of its delayed onset of action.
-Normal potassium levels are generally achieved within 24 to 48 hours; once normal potassium levels are achieved, the minimal effective maintenance dose should be established.
-Dose should be decreased or discontinued if serum potassium is below the desired target range.

Use: For the treatment of hyperkalemia.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended



Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Take orally as a suspension in water
-Other oral medications should be administered at least 2 hours before or 2 hours after this drug (see general comments)

Reconstitution/preparation techniques:
-Empty entire contents of packet(s) into approximately 3 tablespoons of water; stir well and drink immediately; if powder remains, add water, stir and drink immediately; repeat until no powder remains
-Volume of water may be increased as long as entire contents is consumed and no powder remains

-This drug may transiently increase gastric pH; therefore, the absorption of drugs that exhibit pH-dependent solubility may be altered when taken at the same time as this drug. In general, other oral medications should be administered at least 2 hours before or 2 hours after taking this drug unless the concomitantly administered drug does not exhibit pH-dependent solubility.
-This drug has been studied in patients with diseases such as chronic kidney disease, heart failure, and diabetes mellitus.

-Monitor serum potassium levels as clinically indicated
-Monitor for signs of edema

Patient advice:
-Patients should be instructed on proper reconstitution and administration of this drug.
-Patients should be advised to adjust sodium, if appropriate.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.